Sanofi and GlaxoSmithKline Plc, the pharma giants that faltered in the race to develop a COVID-19 shot, found that their vaccine prevents serious illness and hospitalization and will submit data to regulators for approval.
Both said data from a trial shows that two doses of the Sanofi-GSK vaccine have 100% efficacy against severe COVID-19 and hospitalization and 58% efficacy against any symptomatic COVID-19 disease. He added that the safety of the vaccine was also favorable.
Meanwhile, a separate study showed that it can increase antibody levels by 18- to 30-fold when used as a booster in people who have previously received other types of shots.
Shares of Sanofi rose 1.7% in Paris on Wednesday, while GSK in London gained 1.6%.
The data should allow the vaccine giant to eventually play a bigger role in the pandemic’s fight, with repeated development delays allowing Nimbler competitors such as Moderna Inc. and the BioNtech SE-Pfizer Inc alliance to move forward with messenger-RNA products. Got it. Those companies, along with AstraZeneca plc and Johnson & Johnson, rapidly brought highly effective products to market, helping to save millions of lives and generate tens of billions of dollars in revenue.
Sam Fazeli, an analyst at Bloomberg Intelligence, said in a note that while the Sanofi-Glaxo product appears to be on par with mRNA shots in preventing serious illness and hospitalization, efficacy may be somewhat lower in the case of symptomatic disease. Is.
“The vaccine will find a niche among people in low-income countries to pick up mRNA vaccines, with a modest commercial impact on Sanofi and Glaxo,” Fazeli said.
The world has already delivered more than 10 billion doses of COVID vaccines, which means demand is increasingly coming in from poorer countries and booster campaigns.
There are some potential advantages of Sanofi-Glaxo inoculation over most existing COVID shots. It can be kept at refrigerator temperature, making it easier to transport and store than existing mRNA shots. The product also relies on recombinant protein technology that Sanofi uses to enhance an adjuvant immune response from the flu vaccine and Glaxo.
As of now, however, Sanofi and Glaxo are facing a new crop of rivals with Covid shots. For example, Novavax Inc. also has a recombinant-protein product and has been approved by Europe and the World Health Organization since December.
Sanofi and Glaxo’s candidate faced months of delays because the companies accidentally gave participants a lower dose than planned in an early-stage trial.
(Update with additional information on findings, shares in fourth paragraph.)
More stories like this are available at bloomberg.com
©2022 Bloomberg LP
This story has been published without modification in text from a wire agency feed. Only the title has been changed.
Never miss a story! Stay connected and informed with Mint.
download
Our App Now!!
,